Repeated Clozapine Administration Causes Extensive Changes to the Expression of Coding and Non-coding RNAs, Including miR-124, in the Mouse Frontal Cortex
- PMID: 40690135
- DOI: 10.1007/s12035-025-05199-4
Repeated Clozapine Administration Causes Extensive Changes to the Expression of Coding and Non-coding RNAs, Including miR-124, in the Mouse Frontal Cortex
Abstract
Clozapine is arguably the most effective antipsychotic drug for the treatment of schizophrenia, but the mechanisms underlying its efficacy are poorly understood. Therefore, we perform deep RNA sequencing to test for differential transcription and exon use resulting from clozapine's effects in the mouse frontal cortex, and integrate our findings with known schizophrenia risk genes. We used a dose (4 mg/kg/day, i.p.) and duration (21 days) to approximate clinical exposure, followed by a 24-h washout to determine persistent changes resulting from biological remodeling. We observed significant (FDR < 0.05) differential expression of both mRNAs and long noncoding RNAs (lncRNAs), which were enriched in RNA processing and splicing pathways. Among the most significant lncRNAs, showing 2.3-fold upregulation, was the microRNA 124 host gene (Mir124a-1hg), a major source of miR-124, one of the most abundant microRNAs in the brain. Quantitative PCR analysis of the mature microRNAs miR-124-3p and miR-124-5p revealed a significant dose-dependent upregulation of miR-124-3p following 21-day repeated clozapine administration. RNA splicing was also profoundly impacted by clozapine, as revealed by differential exon use analysis, with mouse orthologs of 50 schizophrenia risk genes from the Psychiatric Genomics Consortium among the genes affected. These genes were enriched in "apical dendrite" and "distal axon" ontologies, supporting prior evidence that clozapine may target cortical pyramidal neuron deficits implicated in schizophrenia. Overall, this study demonstrates the profound effect of clozapine on cortical gene expression, affecting abundance of splicing of coding and non-coding transcripts. Future studies are needed to fully characterize our findings as potential preclinical markers of clozapine response.
Keywords: Antipsychotic drugs; Brain; Gene expression; Non-coding RNA; RNA sequencing; Schizophrenia.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethical Approval: This study was approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University. Competing Interests: The authors declare no competing interests.
Similar articles
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
-
Clozapine dose for schizophrenia.Cochrane Database Syst Rev. 2017 Jun 14;6(6):CD009555. doi: 10.1002/14651858.CD009555.pub2. Cochrane Database Syst Rev. 2017. PMID: 28613395 Free PMC article.
-
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.Cochrane Database Syst Rev. 2017 Mar 23;3(3):CD006324. doi: 10.1002/14651858.CD006324.pub3. Cochrane Database Syst Rev. 2017. PMID: 28333365 Free PMC article.
-
Corticosteroids for the treatment of Duchenne muscular dystrophy.Cochrane Database Syst Rev. 2016 May 5;2016(5):CD003725. doi: 10.1002/14651858.CD003725.pub4. Cochrane Database Syst Rev. 2016. PMID: 27149418 Free PMC article.
References
-
- Miyamoto S, Merrill DB, Jarskog LF, Fleishhacker WW, Marder SR, Lieberman JA (2015) Antipsychotic drugs. In: Tasman A, Kay J, Lieberman JA, First MB, Ribe MB (eds) Psychiatry, 4th edn. John Wiley & Sons, Ltd, pp 2088–2128. https://doi.org/10.1002/9781118753378.ch104
-
- Owen MJ, Sawa A, Mortensen PB (2016) Schizophrenia. Lancet 388:86–97. https://doi.org/10.1016/S0140-6736(15)01121-6 - DOI - PubMed - PMC
-
- Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet 382:951–962. https://doi.org/10.1016/S0140-6736(13)60733-3 - DOI
-
- Nucifora FC, Mihaljevic M, Lee BJ, Sawa A (2017) Clozapine as a model for antipsychotic development. Neurotherapeutics 14:750–761. https://doi.org/10.1007/s13311-017-0552-9 - DOI - PubMed - PMC
-
- Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796. https://doi.org/10.1001/archpsyc.1988.01800330013001 - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources